Evaluation of neuroactive steroid levels by liquid chromatography–tandem mass spectrometry in central and peripheral nervous system: Effect of diabetes

Donatella Caruso a, Samuele Scurati a, Omar Maschi a, Leonardo De Angelis a, Ilaria Roglio b, Silvia Giatti b, Luis Miguel Garcia-Segura c, Roberto C. Melcangi b,∗

a Department of Pharmacological Sciences, University of Milan, Milano, Italy
b Department of Endocrinology and Center of Excellence on Neurodegenerative Diseases, University of Milan, Via Balzaretti 9, 20133 Milano, Italy
c Instituto Cajal, C.S.I.C., Madrid, Spain

Received 28 February 2007; received in revised form 11 June 2007; accepted 11 June 2007

© 2007 Published by Elsevier Ltd.

Abstract

The nervous system is a target for physiological and protective effects of neuroactive steroids. Consequently, the assessment of their levels in nervous structures under physiological and pathological conditions is a top priority. To this aim, identification and quantification of pregnenolone (PREG), progesterone (PROG), dihydropregesterone (DHP), tetrahydroprogesterone (THP), testosterone (T), dihydrotestosterone (DHT), 5α-androstan-3α, 17β-diol (3α-diol), 17α- and 17β-estradiol (17α-E and 17β-E) by liquid chromatography and tandem mass spectrometry (LC–MS/MS) has been set up. After validation, this method was applied to determine the levels of neuroactive steroids in central (i.e., cerebral cortex, cerebellum and spinal cord) and peripheral (i.e., brachial nerve) nervous system of control and diabetic rats. In controls only the brachial nerve had detectable levels of all these neuroactive steroids. In contrast, 17α-E in cerebellum, 17α-E, 17β-E, DHP and THP in cerebral cortex, and 17α-E, 17β-E and DHP in spinal cord were under the detection limit. Diabetes, induced by injection with streptozotocin, strongly affected the levels of some neuroactive steroids. In particular, the levels of PREG, PROG and T in cerebellum, of PROG, T and 3α-diol in cerebral cortex, of PROG, DHT and 3α-diol in spinal cord and of PREG, DHP, THP, T, DHT and 3α-diol in brachial nerve were significantly decreased. In conclusion, the data here reported demonstrate that the LC–MS/MS method allows the assessment of neuroactive steroids in the nervous system with high sensitivity and specificity and that diabetes strongly affects their levels, providing a further basis for new therapeutic tools based on neuroactive steroids aimed at counteracting diabetic neuropathy.

Keywords: Streptozotocin; Central nervous system; Peripheral nervous system; Steroid level; Rat; Neuroprotection

1. Introduction

One important complication of diabetes is the damage that may occur at the level of the nervous system. Diabetic peripheral neuropathy occurs in 60–70% of patients affected by type I and type II diabetes and, as described both in human and in animal models. For instance streptozotocin (STZ)-induced neuropathy, is associated with a spectrum of functional (e.g., nerve conduction velocity, expression of myelin proteins, Na+,K+-ATPase activity, nociceptive threshold, etc.) and structural (e.g., axonal degeneration, paranodal demyelination and loss of myelinated fibers) changes in peripheral nerves (Yagihashi, 1997; Biessels et al., 1999; Bianchi et al., 2004; Veiga et al., 2006; Leonelli et al., 2007). Moreover, the impact of diabetes on the central nervous system (CNS) is well recognized. Neuropsychological and structural changes at the level of cerebral areas, such as hypothalamus, cerebral cortex, cerebellum and hippocampus, are associated with cognitive deficits and increased risk of dementia, stroke, cerebrovascular and Alzheimer disease and psychiatric disorders, such as depression and eating disorders (Gispen and Biessels, 2000; Jacobson et al., 2002; Sima et al., 2004; van Harten et al., 2006). It is well known that neuroactive steroids, like for instance pregnenolone (PREG), progesterone (PROG), and its deriva-
atives dihydroprogesterone (DHP) and tetrahydroprogesterone (THP), testosterone (T) and its derivatives dihydrotestosterone (DHT) and 5α-androstane-3α, 17β-diol (3α-diol), and estrogens regulate several physiological processes in neurons and glial cells of the peripheral nervous system (PNS) and CNS (Melcangi et al., 2001, 2002, 2005; García-Segura and Melcangi, 2006).

Moreover, recent observations obtained in our and other laboratories have indicated that these neuroactive steroids exert protective effects in several experimental models of neurodegeneration (Lapchak and Araujo, 2001; Azcoitia et al., 2003; McCulloch and Hurn, 2003; Ciriza et al., 2004; Griffon et al., 2004), including diabetic neuropathy (Veiga et al., 2006; Leonelli et al., 2007; Saravia et al., 2006). Interestingly, the impact of diabetes is also evident on steroid levels. Indeed, several observations have shown dysfunction in the reproductive axis associated with diabetes, with modifications of sex steroid plasma levels (El’tseva et al., 1993; Sudha et al., 2000; Tanaka et al., 2001; van Dam et al., 2003; Salonia et al., 2006). Moreover, we have recently observed that STZ-induced diabetes causes plasma PROG levels to drop steeply in male rats (Leonelli et al., 2007). Furthermore, altered levels of neuroactive steroids occur not only in plasma but also in nervous tissues. It has been recently reported that an increase of PROG biosynthesis concomitant with a decrease of formation of its metabolite, THP, occurs in the spinal cord of rats with STZ-induced diabetes (Saredi et al., 2004). This single report is highly relevant because the modifications of the levels of steroids in neural tissue with diabetes may potentially increase, decrease and/or be the consequence of local pathological damage and may affect the result of therapies based on neuroactive steroids. Consequently, it is extremely important to determine the levels of neuroactive steroids in central and peripheral nervous structures and to assess whether these levels are modified by diabetes.

With this aim, an analytical method based on liquid chromatography and tandem mass spectrometry (LC–MS/MS) for the identification and quantification of PREG, PROG, DHP, THP, T, DHT, 3α-diol, 17α- and 17β-estradiol (17α-E and 17β-E) has been set up. After validation of the LC–MS/MS procedure, this method was applied to the identification and quantitative determination of the neuroactive steroids mentioned above in CNS structures, such as cerebral cortex, cerebellum and spinal cord, and in a peripheral nerve, such as brachial nerve, of control and STZ-treated rats.

2. Experimental procedures

2.1. Materials

5-Pregnen-3β-ol-20-one (PREG), progesterone (PROG), 5α-pregnan-3β, 20-dione (DHP), 3α-hydroxy-5α-pregnen-20-one (THP), testosterone (T), 5α-androstane-17β-3α, 17β-diol (3α-diol), 17α- and 17β-estradiol (17α-E and 17β-E) were purchased from Sigma–Aldrich. 17α,21,21-D4 PREG (D4-PREG) was kindly synthesized by Dr. P. Ferraboschi (Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milano, Italy); 2,2,4,6,6,17α,21,21-D4 PROG (D4-PROG) was obtained from Medical Isotopes (Pelham, NH, USA) and 2,4,16,16-D4-17α-E (D4-17α-E) from CDN Isotope Pointe-Claire (Que., Canada). SPE cartridges (Discovery DS-C18 500 mg) were from Supelco, Italy. All solvents and reagents were HPLC grade (Sigma–Aldrich, Italy).

2.2. LC–MS/MS analysis

Positive atmospheric pressure chemical ionization (APCI+) experiments were performed using a linear ion trap-mass spectrometer (LTQ, ThermoElectron Co., San Jose, CA, USA) equipped with a Surveyor liquid chromatography (LC) Pump Plus and a Surveyor Autosampler Plus (ThermoElectron Co., San Jose, CA, USA).

The LC mobile phases were (A) H2O:0.1% formic acid and (B) methanol (MeOH):0.1% formic acid. The gradient (flow rate 1 ml/min) was as follows: T0 60%, T1 55%, T2 50%, T3 45%, T4 40%, T5 35%, T6 30%, T7 10%, T8 5%, T9 0%. The split valve was set at 0–10 min to waste, 10–50 min to source and 50–65 min to waste. The Isolr-electr ODS-2 RP-C18 column (5 μm, 150 mm × 4.6 mm i.d.; GL Sciences Inc., Japan) was maintained at 40 °C. The injection volume was 25 μl and the injector needle was washed with MeOH/ water 1/1 (v/v). Peaks of the LC–MS/MS were evaluated using a Dell workstation by means of the software Excalibur® release 2.0 SR2 (ThermoElectron Co, San Jose, CA, USA).

The mass spectrometer was operated in the positive ion mode with the atmospheric pressure chemical ionization (APCI) source using nitrogen as sheath gas and sweep gas at flow rates of 23, 8, 2 (arbitrary units), respectively. Other ion-source parameters: vaporizer temperature 450 °C, ion-source collision-energy (SID) 20 V, capillary temperature 275 °C. The mass spectrometer was employed in MSMS mode using helium as collision gas. The relative collision-energy was set at 35% for 17α-E, 17β-E, D4-17α-E, 3α-diol and at 35% using the Wide Band Activation mode (ThermoElectron Co., USA) for all the other steroids. Samples were analyzed employing the transitions reported in Table 1.

2.3. Study design and sample preparation

Two-month-old male Sprague–Dawley rats, Crl:CD BR (Charles River, Italy) were housed in the animal quarters of the Department of Endocrinology at the University of Milan with controlled temperature and humidity. The light schedule was 14 h light and 10 h dark (lights on at 6:30 h). The animals were handled following the European Union Normative (Council Directive 86/609/ EEC guidelines), with the approval of our Institutional Animal Use and Care Committees. Rats were randomly divided into two groups (control and diabetic).

Diabetes was induced by a single injection into the tail vein of freshly prepared STZ (65 mg/kg; Sigma, Italy) in citrate buffer 0.09 M pH 4.8. Control animals were injected with 0.09 M citrate buffer at pH 4.8. Hyperglycemia was confirmed 48 h after STZ injection by measuring tail vein blood glucose levels using a Glucometer test (Menarini, Italy). Only animals with mean plasma glucose levels above 300 mg/dl were classified as diabetic. Three months after the diabetes induction, rats were sacrificed and cerebral cortex, cerebellum, spinal cord and brachial nerve were collected, weighed and stored at −80 °C before the analysis.

**Table 1**

<table>
<thead>
<tr>
<th>Analytical parameters</th>
<th>Precursor ions</th>
<th>Transition monitored</th>
<th>RRT</th>
<th>IS</th>
<th>Segment</th>
</tr>
</thead>
<tbody>
<tr>
<td>D4-17β-E</td>
<td>259</td>
<td>161</td>
<td>1</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>17β-E</td>
<td>255</td>
<td>133, 159</td>
<td>1.01</td>
<td>D4-17β-E</td>
<td>1</td>
</tr>
<tr>
<td>17α-E</td>
<td>255</td>
<td>133, 159</td>
<td>1.08</td>
<td>D4-17β-E</td>
<td>1</td>
</tr>
<tr>
<td>T</td>
<td>289</td>
<td>97, 109</td>
<td>1.07</td>
<td>D4-17β-E</td>
<td>1</td>
</tr>
<tr>
<td>D4-PROG</td>
<td>324</td>
<td>100</td>
<td>1</td>
<td>–</td>
<td>2</td>
</tr>
<tr>
<td>DHT</td>
<td>315</td>
<td>97, 109</td>
<td>1.02</td>
<td>D4-PROG</td>
<td>2</td>
</tr>
<tr>
<td>3α-Diol</td>
<td>291</td>
<td>255</td>
<td>0.89</td>
<td>D4-PROG</td>
<td>2</td>
</tr>
<tr>
<td>17α,21,21-D4 PREG</td>
<td>257</td>
<td>121, 135, 147</td>
<td>1.08</td>
<td>D4-PROG</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>161</td>
<td>1</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>D4-PREG</td>
<td>303</td>
<td>175</td>
<td>1</td>
<td>–</td>
<td>3</td>
</tr>
<tr>
<td>PROG</td>
<td>299</td>
<td>159, 199</td>
<td>1.01</td>
<td>D4-PREG</td>
<td>3</td>
</tr>
<tr>
<td>DHP</td>
<td>299</td>
<td>189</td>
<td>1.05</td>
<td>D4-PREG</td>
<td>3</td>
</tr>
<tr>
<td>THP</td>
<td>301</td>
<td>159, 173, 187</td>
<td>1.27</td>
<td>D4-PREG</td>
<td>3</td>
</tr>
</tbody>
</table>

RRT: relative retention time (calculated against the IS monitored in the corresponding segment); IS: internal standard.
4.2. Quantitative analysis and analytical method validation

4.2.1. Calibration curves
Quantitative analysis was performed on the basis of calibration curves daily prepared and analyzed: blank samples (6% albumin in PBS) were spiked with 

\[ D_2-17\beta-E \ (1 \text{ ng/sample}), \ D_6-PROG \ (0.2 \text{ ng/sample}) \text{ and } D_6-PREG \ (5 \text{ ng/sample}) \], as internal standards. Increasing amounts (0.05–5 ng/sample) of each steroid were added. Calibration curves were extracted and analyzed as already described for samples.

4.2.2. Limit of quantification, precision and accuracy
The limit of quantification (LOQ) was calculated as the lowest amount of steroid measured with a minimum error of ±20% in triplicate, as described by Vallée and collaborators (Vallée et al., 2000).
Inter-assay accuracy and reproducibility of the method were calculated over a series of blank samples spiked with 0.5, 2.5 and 5 ng/sample and estimated on the basis of calibration curves. Accuracy was calculated by the ratio (obtained value/true value × 100) in different five samples prepared and injected in duplicate in different days. Precision was determined as coefficient of variation (CV%) calculated on the basis of five samples prepared and injected in different days.

4.2.3. Statistical analysis
The linearity of the standard curve \( \left( r^2 \right) \), the accuracy (%) and the precision (CV%) inter-series were judged by GraphPad Prism (version 4). Student’s \( t \)-test was used to determine significant differences between control and diabetic tissues.

3. Results
The present approach is based on the power of tandem mass spectrometry. The increase of specificity (also reflecting an improvement of sensitivity) achieved with this method represents the basis for unambiguous identification of the analytes. Their structural identification is based not only on the molecular ion and retention time, but also on specific fragmentation routes specifically related to the structure. Therefore, the described method allows the identification and quantification of PREG, PROG, DHP, THP, T, DHT, 3α-diol, 17α-E and 17β-E in nervous tissues with satisfactory standards of linearity, precision, accuracy and sensitivity (Table 2).

The correlation coefficient values \( \left( r^2 \right) \) were greater than 0.99, indicating an adequate linearity of our analytical procedure. As shown in this table, accuracy and reproducibility were within the accepted tolerances even at the lowest concentration level studied (93–108%; CV% <15). As expected, the highest values were obtained at the lower concentrations and for DHP, for which the LOQ is very high due to a difficulty in the ionization.

Fig. 2 shows representative examples of ion chromatograms and the mean of five calibration curves prepared and analyzed in different days. In the first segment of the analysis (14–18 min, panel A) 17α-E, 17β-E and T were detected. These compounds were quantified using \( D_2-17\beta-E \) as internal standard; the linearity of the determinations was presented in the right part of the panel A. Similarly, panels B and C show the second (18–32 min) and the third (32–47 min) segments of the analysis and the respective calibration curves. All the compounds were discernible on the basis of different ion and/or retention times.

Fig. 2 shows the levels of neuroactive steroids in cerebellum of control and STZ-treated rats. All neuroactive steroids analyzed, with the exception of 17α-E, were identified and measured in control animals. A significant impact of three months of diabetes was evident. In particular, PREG, PROG and T levels were significantly decreased in cerebellum of STZ-treated rats. On the contrary, metabolites of PROG (i.e., DHP and THP) or of T (i.e., DHT and 3α-diol) as well as the levels of 17β-E were unaffected by diabetes. A different pattern of steroid levels in control and STZ-rats was present in the other two CNS regions analyzed. In particular, as shown in Fig. 3, only PREG, PROG, T and its derivatives (i.e., DHT and 3α-diol) were detected in the cerebral cortex of control animals. Among

Table 2
Validation of the method

<table>
<thead>
<tr>
<th>LOQ (pg/sample)</th>
<th>Level 0.5</th>
<th>Level 2.5</th>
<th>Level 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Accuracy</td>
<td>Precision CV%</td>
<td>Accuracy</td>
</tr>
<tr>
<td>PREG</td>
<td>0.999</td>
<td>0.05</td>
<td>96</td>
</tr>
<tr>
<td>PROG</td>
<td>0.990</td>
<td>0.05</td>
<td>105</td>
</tr>
<tr>
<td>DHP</td>
<td>0.990</td>
<td>0.25</td>
<td>101</td>
</tr>
<tr>
<td>THP</td>
<td>0.998</td>
<td>0.1</td>
<td>93</td>
</tr>
<tr>
<td>T</td>
<td>0.999</td>
<td>0.02</td>
<td>109</td>
</tr>
<tr>
<td>DHT</td>
<td>0.992</td>
<td>0.05</td>
<td>102</td>
</tr>
<tr>
<td>3α-Diol</td>
<td>0.992</td>
<td>0.05</td>
<td>107</td>
</tr>
<tr>
<td>17α-E</td>
<td>0.999</td>
<td>0.02</td>
<td>105</td>
</tr>
<tr>
<td>17β-E</td>
<td>0.999</td>
<td>0.02</td>
<td>102</td>
</tr>
</tbody>
</table>

\( r^2 \): linearity of the assay calculated on the basis of almost four calibration curves; LOQ: limit of quantification; accuracy is calculated as obtained value/true value × 100 (five samples prepared and injected in different days) on the basis of the calibration curves; precision is calculated as CV% (five samples prepared and injected in different days).
these only the levels of PROG, T and 3α-diol were significantly decreased by diabetes. The levels of DHT observed in the cerebral cortex of STZ-treated rats were under the detection limit, but not significantly different from those observed in control rats. It is interesting to note that in the cerebral cortex of both control and diabetic rats, the levels of DHP, THP, 17α-E and 17β-E were under the detection limit.

Most steroids analyzed were detected and measured in the spinal cord of control and diabetic animals, with the exception of DHP, 17α-E and 17β-E (Fig. 4). PROG, DHT and 3α-diol were significantly decreased in the spinal cord of diabetic animals, while PREG, T, and THP were unaffected by diabetes. Interestingly, the levels of 17β-E, which were under the detection limit in the spinal cord of control animals, were detectable in diabetic animals.

As shown in Fig. 5, brachial nerves of control animals showed detectable levels of all neuroactive steroids and the impact of diabetes was evident with most of them, with the exception of PROG, 17α-E and 17β-E. In particular, PREG, DHP, THP, T, DHT and 3α-diol levels decreased significantly in brachial nerve of diabetic animals.

4. Discussion

The advent of robust and analytically reliable techniques based on the combination of liquid chromatography (LC) and tandem mass spectrometry (LC–MS/MS) has enabled the quantification of endogenous 3α-hydroxysteroids and their 17β-epimers in various tissues. These techniques have been recently exploited and applied to the analysis of brain and peripheral nerve samples in several experimental models of neurodegeneration and neuroinflammation. In the present study, we have evaluated the levels of neuroactive steroids in the central (cerebral cortex) and peripheral (spinal cord and brachial nerves) nervous system of control and diabetic rats.
mass spectrometry (MS) by means of atmospheric pressure ionization (API) (e.g., electrospray, ESI and atmospheric pressure chemical ionization, APCI) and in particular the improvements brought about by tandem MS (MS/MS), has opened new perspectives in terms of mass spectrometric identification and quantification of steroids that are difficult to analyze by gas chromatography–MS. With respect to the ionization mode, APCI is mainly applied to rather less polar compounds than ESI but is less susceptible to ion suppression due to the presence of several interferences as is the case in biological tissues. For quantitative assays employing MS detection, triple quadrupole systems are most commonly used, while the new generation of ion trap, namely the linear trap, exhibits similar performance, as also demonstrated by our results. In addition, when an APCI-linear trap is operated in the MS/MS mode, the identification and quantification of the analytes are based on both precursor and product ions, giving higher selectivity and better sensitivity than for any other MS system. Based on these factors, we set up the analytical method reported here, which permitted to simultaneously measure several neuroactive steroids in cerebral cortex, cerebellum, spinal cord and brachial nerve. Data obtained have indicated that these nervous structures did not show the same pattern of distribution of the neuroactive steroids under consideration. For instance, it is interesting to note that only the brachial nerve showed the presence of all these neuroactive steroids (i.e., PREG, PROG, DHP, THP, T, DHT, 3α-diol, 17α-E and 17β-E). In the central nervous system, the cerebellum showed detectable levels of all these neuroactive steroids with the exception of 17α-E. In contrast, the cerebral cortex seems to be unable to produce or accumulate PROG metabolites (i.e., DHP and THP) as well as 17α-E and 17β-E. A similar pattern is evident in the spinal cord, where DHP, 17α-E and 17β-E were under detection limits. Levels of PROG metabolites as well as of 17α-E and 17β-E in cerebral cortex and spinal cord are in apparent disagreement with observations available in the literature indicating that these two nervous structures seem to express the enzymes producing PROG metabolites (i.e., 5α-reductase and 3α-hydroxysteroid dehydrogenase (Melcangi et al., 1987; Stoffel-Wagner, 2003; Patte-Mensah et al., 2004; Agis-Balboa et al., 2006) and converting T into estrogens (i.e., aromatase) (Evrard and Balthazart, 2003; Stoffel-Wagner, 2003; Yague et al., 2006). The discrepancy between the local levels of steroids and the local expression of steroidogenic
enzymes suggests that PROG metabolites and estrogens are rapidly cleared in the cerebral cortex and the spinal cord. In addition, levels of expression of steroidogenic enzymes may not necessarily reflect their levels of activity.

The results reported here also indicate that diabetes, induced by injection with STZ, strongly affects the levels of neuroactive steroids. Generally a decrease both in the CNS and PNS was observed. In some cases the effects of diabetes on steroid levels in neural tissue did not completely reflect the changes previously reported in plasma. For instance, the levels of PREG in the brachial nerve and cerebellum of diabetic rats reported here show a significant decrease, but remain unchanged in plasma (Leonelli et al., 2007). These findings suggest that diabetes differentially alters steroid synthesis in endocrine glands and nervous structures. Indeed, formation of PREG and other steroids in the peripheral and central nervous systems is not surprising. It has been clearly established that glial cells of the peripheral and central nervous systems express molecules, such as translocator Protein-18 kDa (TSPO, formerly known as peripheral benzodiazepine receptor) and steroidogenic acute regulatory protein, able to participate in the transport of cholesterol to the inner mitochondrial membrane where cytochrome P450scc (i.e., the enzyme forming PREG) is located (Garcia-Segura and Melcangi, 2006). An altered neurosteroidogenesis has been also observed in different forms of neural injury and different neuropathological conditions. For instance, TSPO basal expression is upregulated in gliomas, in neurodegenerative disorders, and in various forms of brain injury and inflammation (Papadopoulos et al., 2006). A very similar effect occurs in the PNS, where the expression of TSPO is increased in Schwann cells after nerve lesion and returns to normal levels when regeneration is completed (Lacor et al., 1999). This induction has been interpreted as reflecting an endogenous increase in steroidogenesis as a neuroprotective response to the damage. In agreement with that, an increased biosynthesis of PROG has been detected in the spinal cord of diabetic animals using HPLC combined with a continuous flow scintillation detection method (HPLC-Flo/one method) utilizing exogenous substrate (tritiated PREG) to evaluate PROG formation (Saredi et al., 2005). It is clear that the endogenous mechanism triggered by diabetes is certainly not enough to protect the nervous system efficiently. Furthermore, although PROG biosynthesis is increased, we demonstrate here that PROG levels are decreased in spinal cord of diabetic animals, suggesting an increased PROG metabolism. In this regard it is also important to note that while the levels of PROG are...
decreased, the levels of its metabolite THP are unaffected by diabetes, further suggesting an enhanced PROG metabolism in the spinal cord of diabetic animals.

The decrease of the levels of several neuroactive steroids associated with diabetes is also interesting in relation with the protective effect exerted by some of these molecules. Indeed, recent observations have shown that neuroactive steroids might provide a new therapeutic tool for damage induced by diabetes both in PNS and CNS. For instance, dehydroepiandrosterone prevents vascular and neuronal dysfunction in the sciatic nerve of STZ-treated rats (Yorek et al., 2002). In the same experimental model, we recently observed that PROG and its derivatives, DHP and THP, reversed the impairment of nerve conduction velocity and thermal threshold, restored intra-epidermal nerve fiber density, improved Na⁺,K⁺-ATPase activity, and counteracted the decrease of gene expression of myelin proteins, such as glycoprotein zero and peripheral myelin protein 22 (Leonelli et al., 2007). We also observed that PROG or DHP administration results in a significant reduction in the number of fibers with myelin abnormalities in the sciatic nerve of STZ-treated rats (Veiga et al., 2006).

Neuroactive steroids are also protective against detrimental effects of diabetes mellitus on the CNS. For instance, estrogens can increase the regional brain glucose utilization in diabetic (db/db) mice (Garris, 1999). Moreover, as demonstrated in STZ-rats, treatment with 17β-E may have a beneficial effect in dementia disorders associated with diabetes (Lannert et al., 1998), and, as demonstrated in Bio Breeding (BB) diabetic rats, decreases the infarct size after temporary focal ischemia (Toung et al., 2000). Furthermore, it has been recently demonstrated that 17β-E stimulates brain neurogenesis and exerts protective effects at hippocampus level in STZ mice (Saravia et al., 2006).

In conclusion, the data reported here demonstrate that the LC–MS/MS method described allows the assessment of neuroactive steroids in structures of CNS and PNS with high...
sensitivity and specificity. By means of this methodological procedure, we observed that diabetes strongly affects the levels of several neuroactive steroids in the CNS and PNS. This finding provides a further basis for the proposal of a therapeutic strategy based on neuroactive steroids aimed at counteracting the neurodegenerative effects of diabetes.

Acknowledgements

The financial supports of PRIN (2005060584_004) and FIRST from University of Milan, Italy to R.C.M. are gratefully acknowledged.

References


